Click on a filter below to refine your search. Remove a filter to broaden your search.
An increased risk was seen for fatigue and chronic fatigue, with hazard ratios of 1.68 and 4.32 compared with non-COVID-19 controls.
Cefepime-taniborbactam was superior for composite success, which included microbiologic and clinical success.